Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.
